Compare CKX & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | CTXR |
|---|---|---|
| Founded | 1930 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 19.8M |
| IPO Year | 1998 | N/A |
| Metric | CKX | CTXR |
|---|---|---|
| Price | $9.26 | $1.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 3.2K | ★ 521.9K |
| Earning Date | 11-10-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.14 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $897,333.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $41.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.66 | $0.65 |
| 52 Week High | $14.00 | $5.95 |
| Indicator | CKX | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 41.57 |
| Support Level | $9.15 | $1.12 |
| Resistance Level | $9.67 | $1.20 |
| Average True Range (ATR) | 0.44 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 33.52 | 1.14 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. CKX has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Surface segment. Geographically, it generates all of its revenue from the United States of America.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.